ArticleTH open : companion journal to thrombosis and haemostasis2020
Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis.
Article in TH open : companion journal to thrombosis and haemostasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 6 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis.Blood advances · 2022Guideline
- [COVID-19 and thromboprophylaxis: Recommendations for our clinical practice in Primary Care].Semergen · 2020Guideline
- Guideline
- Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.Journal of thrombosis and haemostasis : JTH · 2020Guideline
- Hematological findings and complications of COVID-19.American journal of hematology · 2020Pooled it
- Diagnostic Value of D-Dimer in COVID-19: A Meta-Analysis and Meta-Regression.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.Journal of the American Heart Association · 2021Trial
- Arterial and venous thromboembolism in hospitalized patients with COVID-19: a national multicenter cohort study.Blood vessels, thrombosis & hemostasis · 2026Article
- Article
- Risk Stratification in Pulmonary Embolism: Prognostic Value of PESI, WELLS, PADUA, and IMPROVE Scores in Relation to Laboratory Markers.Journal of clinical medicine · 2026Article
- Venous thromboembolism prophylaxis in postacute care units: a health record review.Research and practice in thrombosis and haemostasis · 2026Article
- Derivation of a novel risk assessment model of venous thromboembolism in hospitalized patients.PeerJ · 2026Article
- Facts and Misfacts on D-Dimer Testing. Consensus Guidance From the Italian Society on Thrombosis and Hemostasis (SISET).American journal of hematology · 2026Review
- Prophylactic vs. Intermediate Tinzaparin Dosage for the Thromboprophylaxis of Acutely Ill Medical Patients at High Risk of Venous Thromboembolism.Medical sciences (Basel, Switzerland) · 2025Article
- Risk factors for venous thrombosis after discharge from medical hospitalizations: the Medical Inpatient Thrombosis and Hemostasis study.Journal of thrombosis and haemostasis : JTH · 2025Article
- The COVID-19 thrombus: distinguishing pathological, mechanistic, and phenotypic features and management.Journal of thrombosis and thrombolysis · 2025Review
- A comprehensive review of venous thromboembolism risk assessment models for hospitalized medical patients: comparative evidence, implementation challenges, and future directions.Frontiers in cardiovascular medicine · 2025Review
- Validation of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) risk scores for venous thromboembolism and bleeding in an independent population.Research and practice in thrombosis and haemostasis · 2024Article
- System-Wide Thromboprophylaxis Interventions for Hospitalized Patients at Risk of Venous Thromboembolism: Focus on Cross-Platform Clinical Decision Support.Journal of clinical medicine · 2024Review
- Construction and validation of risk prediction models for pulmonary embolism in hospitalized patients based on different machine learning methods.Frontiers in cardiovascular medicine · 2024Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An individualized approach to identify acutely ill medical patients at increased risk of venous thromboembolism (VTE) and a low risk of bleeding to optimize the benefit and risk of extended thromboprophylaxis (ET) is needed. The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) VTE risk score has undergone extensive external validation in medically ill patients for in-hospital use and a modified model was used in the MARINER trial of ET also incorporating an elevated D-dimer. The MAGELLAN study demonstrated efficacy with rivaroxaban but had excess bleeding. This retrospective analysis investigated whether the modified IMPROVE VTE model with an elevated D-dimer could identify a high VTE risk subgroup of patients for ET from a subpopulation of the MAGELLAN study, which was previously identified as having a lower risk of bleeding. We incorporated the modified IMPROVE VTE score using a cutoff score of 4 or more or 2 and 3 with an elevated D-dimer (>2 times the upper limit of normal) to the MAGELLAN subpopulation. In total, 56% of the patients met the high-risk criteria. In the placebo group, the total VTE event rate at Day 35 was 7.94% in the high-risk group and 2.83% for patients in the lower-risk group. A reduction in VTE was observed with rivaroxaban in the high-risk group (relative risk [RR]: 0.68, 95% confidence interval [CI]: 0.51-0.91,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.